Liminal BioSciences Inc. (LMNL)

NASDAQ: LMNL · IEX Real-Time Price · USD
3.53
0.00 (0.00%)
Mar 30, 2023, 9:30 AM EDT - Market open
Market Cap 10.96M
Revenue (ttm) 292,701
Net Income (ttm) 543,066
Shares Out 3.10M
EPS (ttm) 0.12
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 363
Open 3.53
Previous Close 3.53
Day's Range 3.53 - 3.53
52-Week Range 3.10 - 10.70
Beta 30.77
Analysts Sell
Price Target 1.22 (-65.44%)
Earnings Date May 8, 2023

About LMNL

Liminal BioSciences Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company's lead product candidate is fezagepras (PBI-4050), which has been completed Phase I clinical trial for the treatment of idiopathic pulmonary, liver, cardiac, or skin fibrosis with fezagepras or related derivatives and respiratory diseases. It is also developing antagonist candidate programs, including G-protein c... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Mr. Bruce Pritchard BA, CA, FIOD
Employees 251
Stock Exchange NASDAQ
Ticker Symbol LMNL
Full Company Profile

Financial Performance

In 2022, LMNL's revenue was 401,000, a decrease of -37.64% compared to the previous year's 643,000. Earnings were 744,000, a decrease of -93.56%.

Financial numbers in CAD Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for LMNL stock is "Sell." The 12-month stock price forecast is $1.22, which is a decrease of -65.44% from the latest price.

Price Target
$1.22
(-65.44% downside)
Analyst Consensus: Sell
Stock Forecasts

News

Liminal BioSciences Reports Fourth Quarter and Year Ended 2022 Financial Results

CTA-enabling work on track to seek approval to commence Phase 1 clinical trial of LMNL6511 during the second half of 2023 Addition of GPR40 agonist discovery program aiming for the development of a no...

2 weeks ago - PRNewsWire

Liminal BioSciences to Report Fourth Quarter and Year Ended 2022 Financial Results on March 15, 2023

LAVAL, QC, and CAMBRIDGE, England , March 13, 2023 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), today announced that it plans to report its fourth q...

2 weeks ago - PRNewsWire

Liminal BioSciences Regains Compliance with NASDAQ Minimum Bid Price Requirement

LAVAL, QC , Feb. 15, 2023 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), announced that it has received written notice from The Nasdaq Stock Market LL...

1 month ago - PRNewsWire

Liminal BioSciences Announces Reverse Stock Split

LAVAL, QC and CAMBRIDGE, England , Jan. 26, 2023 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), announced that a consolidation of all of the issued an...

2 months ago - PRNewsWire

Liminal BioSciences to Present at BIO CEO & Investor Conference

LAVAL, QC and CAMBRIDGE, England , Jan. 19, 2023 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), announced that Bruce Pritchard, Chief Executive Office...

2 months ago - PRNewsWire

Liminal BioSciences Announces Priorities For 2023

Closed December 2022 with just over CAD 37 million cash on hand, expecting to provide a runway into early 2024. Plans to divest its remaining non-core assets, to further extend runway.

2 months ago - PRNewsWire

Liminal BioSciences Announces Holding of Special Meeting of Shareholders

LAVAL, QC and CAMBRIDGE, England , Nov. 25, 2022 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), announced that it will be holding a virtual special me...

4 months ago - PRNewsWire

Liminal BioSciences Reports Third Quarter 2022 Financial Results and Business Highlights

$40.8M of cash and cash equivalents at September 30, 2022 Discontinuation of fezagepras development Termination of legacy CDMO agreement for cash savings of $33.1 million Net loss from continuing oper...

5 months ago - PRNewsWire

Liminal BioSciences to Report Third Quarter 2022 Financial Results on November 9, 2022

LAVAL, QC and CAMBRIDGE, England , Nov. 8, 2022 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), today announced that it plans to report its third quart...

5 months ago - PRNewsWire

Liminal BioSciences Announces Listing Transfer to Nasdaq Capital Market

LAVAL, QC and CAMBRIDGE, England , Sept. 1, 2022 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company") announced today that it received confirmation from the ...

7 months ago - PRNewsWire

Liminal Biosciences to Present at H.C. Wainwright 24th Annual Global Investment Conference

LAVAL, QC and CAMBRIDGE, England , Aug. 29, 2022 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a development-stage biopharmaceutical company, announc...

7 months ago - PRNewsWire

Liminal BioSciences Announces Termination of Legacy CDMO Contract

Termination results in anticipated cash savings of $33.1 million Removes last of legacy contracts associated with former plasma-derived therapeutics business LAVAL, QC and CAMBRIDGE, ENGLAND , Aug. 25...

7 months ago - PRNewsWire

Liminal BioSciences Reports Second Quarter 2022 Financial Results and Business Highlights

$55.8M of cash and cash equivalents at June 30, 2022 Discontinuation of fezagepras development Net loss from continuing operations of $6.5 million during the quarter ended June 30, 2022 compared to $1...

8 months ago - PRNewsWire

Liminal (LMNL) Ends Development of Lead Candidate, Stock Down

Based on results from an early-stage study, Liminal BioSciences (LMNL) decides to discontinue the development of its lead pipeline candidate, fezagepras.

8 months ago - Zacks Investment Research

Liminal BioSciences Announces Discontinuation of Fezagepras Development

LAVAL, QC and CAMBRIDGE, England , July 21, 2022 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company") today announced that it has discontinued development of...

8 months ago - PRNewsWire

Liminal BioSciences Announces Voting Results of its 2022 Annual General Meeting of Shareholders

LAVAL, QC and CAMBRIDGE, England , June 6, 2022 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company") announced the voting results from its Annual General Mee...

10 months ago - PRNewsWire

Liminal BioSciences Announces First Subject Dosed in Phase 1a Single Ascending Dose Clinical Trial of Fezagepras

LAVAL, QC and CAMBRIDGE, England , May 23, 2022 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), today announced that the first subject has been dosed i...

11 months ago - PRNewsWire

Liminal BioSciences Inc. (LMNL) Could Find Support Soon, Here's Why You Should Buy the Stock Now

Liminal BioSciences Inc. (LMNL) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions...

11 months ago - Zacks Investment Research

Liminal BioSciences Reports First Quarter 2022 Financial Results and Business Highlights

Planned Phase 1a Single Ascending Dose ("SAD") clinical trial of fezagepras expected to commence in Q2 2022 Completion of analysis of safety and pharmacokinetic ("PK") data from Phase 1 Multiple Ascen...

11 months ago - PRNewsWire

Liminal BioSciences to Report First Quarter 2022 Financial Results on May 10, 2022

LAVAL, QC and CAMBRIDGE, ENGLAND , May 9, 2022 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), today announced that it plans to report its first quarte...

11 months ago - PRNewsWire

Liminal Biosciences to Present at Upcoming Investor Conferences

LAVAL, QC, and CAMBRIDGE, England , May 9, 2022 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, announced t...

11 months ago - PRNewsWire

Liminal BioSciences Reports Fourth Quarter and Year End 2021 Financial Results

Planned Phase 1a Single Ascending Dose ("SAD") clinical trial, commencing in Q2 2022, to compare fezagepras with sodiumphenylbutyrate as a nitrogen scavenger Repayment in full of the $39.1M secured lo...

1 year ago - PRNewsWire

Liminal BioSciences Provides Update on Its Lead Drug Candidate Fezagepras

Analysis of PK data from Phase 1 Multi-Ascending Dose ("MAD") clinical trial completed Data observed shows that fezagepras has nitrogen scavenging properties Planned Phase 1a Single Ascending Dose ("S...

1 year ago - PRNewsWire

Liminal BioSciences Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement

LAVAL, QC, and CAMBRIDGE, ENGLAND , March 7, 2022 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), announced today that on March 4, 2022, it received a ...

1 year ago - PRNewsWire

Liminal BioSciences Repays its Secured Debt Ending its Creditor Relationship with Structured Alpha LP

Repayment eliminates total debt of $39.1M Early Repayment results in: Total interest savings of CA$9.1M Immediate termination of Loan Agreement and release of security interests over all of its secure...

1 year ago - PRNewsWire